Summary
CONTIPHARMA has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2024 annual accounts show equity of €2.2m and a net result of -€151,785. Equity is shrinking by ~3.3% per year across the filed fiscal years. Its solvency ranks better than 36% of 6131 sector peers (fiscal year 2024). The company has been active since 1999 and the Belgian State Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
3 holdings · 4 subsidiaries in the treeHoldings 3
-
100%
- Bedelco East EuropeROsubsidiarySourceown accounts 2023100%
-
85%
All subsidiaries, including indirect ones 4
Companies in which this company or one of its subsidiaries holds more than half, or which it consolidates according to the LEI register.
According to the 2023 annual accounts of CONTIPHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Companies Code and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No directors read yet: 0 of 7 Gazette acts processed.